Search results for "Sorafenib intolerance"

showing 1 items of 1 documents

Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.

2020

Background & Aims: Limited data on treatment of elderly patients with hepatocellular carcinoma (HCC) increase the unmet need. REACH and REACH-2 were global phase III studies of ramucirumab in patients with HCC after prior sorafenib, where patients with alpha-fetoprotein (AFP) ≥400 ng/mL showed an overall ssurvival (OS) benefit for ramucirumab. These post-hoc analyses examined efficacy and safety of ramucirumab in patients with HCC and baseline AFP ≥ 400 ng/mL by three prespecified age subgroups (<65, ≥65 to <75 and ≥75 years). Methods: Individual patient data were pooled from REACH (baseline AFP ≥400 ng/mL) and REACH-2. Kaplan-Meier and Cox proportional hazards regression methods …

Sorafenibmedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinoma[SDV.CAN]Life Sciences [q-bio]/CancerSorafenib intolerancePlaceboAntibodies Monoclonal HumanizedGastroenterologyRamucirumabRamucirumabCàncer de fetge03 medical and health sciences0302 clinical medicineElderlyInternal medicineCox proportional hazards regressionMedicineHumansAgedHepatologyElevated alpha-fetoproteinbusiness.industryPersones grans dependentsHazard ratioLiver Neoplasms[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyHepatitis CSorafenibmedicine.diseaseFrail elderly3. Good healthVEGFR2Treatment Outcome030220 oncology & carcinogenesisHepatocellular carcinoma[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology030211 gastroenterology & hepatologyMonoclonal antibodiesAlpha-fetoprotein (AFP)alpha-FetoproteinsbusinessAnticossos monoclonalsLiver cancermedicine.drugLiver international : official journal of the International Association for the Study of the LiverREFERENCES
researchProduct